Hindustan Bio Sciences Limited has announced that its board of directors will meet on May 30, 2026, to discuss and approve the audited financial results for the quarter and fiscal year ended March 31, 2026. The meeting is scheduled to take place at 2:00 p.m. at the company's registered office located in Banjara Hills, Hyderabad.

Agenda for the Meeting

The primary focus of the board meeting will be the consideration of the company's financial performance for the fourth quarter and the full financial year 2025-26. Alongside the financial results, the board will review the audit report for the year ended March 31, 2026. Additionally, the directors may discuss any other matters with the permission of the chair.

Meeting Details

The notification to the exchange, dated May 19, 2026, outlines the logistical details of the upcoming gathering. The meeting will be held physically at the company's corporate office.

The intimation was submitted in compliance with Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Hindustan Bio Sciences Limited has submitted its quarterly regulatory certificate to BSE Limited, confirming compliance with SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing demonstrates the company's adherence to mandatory quarterly reporting requirements under securities market regulations.

Quarterly Dematerialization Report

The company reported no dematerialization activity during the fourth quarter of FY26. According to the certificate filed under Regulation 74(5), no equity shares were received for dematerialization during the entire quarter.

Regulatory Compliance Framework

The certificate was prepared based on confirmation received from M/s. Venture Capital and Corporate Investments Pvt. Ltd., which serves as the company's Registrar and Share Transfer Agent. This third-party verification ensures accuracy and compliance with SEBI's regulatory framework for depositories and participants.

The Registrar and Share Transfer Agent independently confirmed in their certificate dated April 6, 2026, that no securities were received for dematerialization or rematerialization during the quarter. This dual-layer verification process strengthens the reliability of the reported information.

Corporate Governance

The certificate was signed by Venkata Rama Mohan Raju Jampana, Managing Director of Hindustan Bio Sciences Limited, bearing DIN: 00060800. The document was digitally signed on April 14, 2026, reflecting the company's adoption of digital processes for regulatory compliance.

Market Context

The absence of dematerialization activity during Q4 FY26 indicates stable shareholding patterns without significant physical-to-electronic share conversions. This quarterly nil report fulfills the company's obligation to maintain transparency with stock exchanges and depositories regarding share transfer activities.

The filing to BSE Limited's Department of Corporate Services ensures that all stakeholders, including investors and regulatory authorities, have access to current information about the company's dematerialization status as required under securities market regulations.